Company intelligence / Profile preview
Everest Medicines
Shanghai, Shanghai, Chinaeverestmedicines.com ↗
- Ownership
- Public · 1952
- Employees
- ~665
- Development stage
- Other
01
Overview
Everest Medicines has successfully commercialized products including VELSIPITY for ulcerative colitis (approved in Macau and Singapore) and Nefecon (TARPEYO) for renal diseases. The company has received full approval from China's NMPA for Nefecon in May 2024.
- Therapeutic areas
- ImmunologyCardiovascularInfectious DiseasesNephrology
- Modalities
- Pharmaceutical productsvaccinesmRNA therapeutics
- Industry
- Biotech
02
Drug pipeline
10 assets9 more assets in the full pipeline.
03
Partnerships
Kezar Life Sciences (zetomipzomib)Providence Therapeutics (COVID-19 vaccine)Venatorx Pharmaceuticals (cefepime/VNRX-5133)Calliditas Therapeutics (Nefecon)
04
Financials
- Market cap
- $1.2B
- Total revenue
- $255.9M
- Enterprise value
- $1.2B
Beyond the preview
Go deeper on Everest Medicines.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Everest Medicines.